According to a study conducted by the National Institute of Neurological Disorders and Stroke (NINDS) that is part of the National Institutes of Health (NIH), an intravenous injection of recombinant tissue plasminogen activator (r-TPA) administered within 3 h of the onset of symptoms is significantly effective in treating stroke patients without them having to undergo surgery [5,6]. This evidence concerns the gene PLAT and Stroke.